Redeye returns with more insights on the Q3 report, and we continue to feel confident in OssDsign’s capabilities in increasing Catalyst sales in the coming quarters. We also highlight next year’s clinical data publications as share price drivers. Following the report, we make no particular changes to our estimates or valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

OssDsign Q3 - Catalyst is growing as expected

© Modular Finance, source Nordic Press Releases